AstraZeneca Reports Higher Profits, But Cuts R&D Jobs
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's patent expiry woes clear amid disappointing '09 results.
You may also be interested in...
AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results
AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
In China alone, the Big Pharma notes net sales were up 36 percent year over year.
AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
In China alone, the Big Pharma notes net sales were up 36 percent year over year.